Media Releases › Immutep View All Immutep News Immutep - Regulatory Clearance received for Phase 1 trial of IMP761 17 Jul 2024 09:18 AM Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA – 17 July 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearance from the ethics and competent authority in the Netherlands to initiate the first-in-human Phase I study of IMP761. For more information, download the attached PDF. Download this document
